Free tool
Drug Trial Radar: Psychiatry
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
14
Not yet recruiting, industry sponsors, Psychiatry, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed532
14 trials
Showing 1 to 14, recently updated first.
- Safety, Tolerability and Efficacy of RGH-202 in Social Anxiety Disorder (STAGE)Pivotal-lookingNot yet recruiting
Gedeon Richter Plc.Industry
NCT07931703 · 156 participants (planned) · Start Nov 12, 2026 · Primary completion Feb 13, 2028
Drug: RGH-202; Placebo · For: Social Anxiety Disorder
Sites: Encino, California; Jacksonville, Florida; Orlando, Florida · 7 sites in all
- Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use DisorderNot yet recruiting
Clive MichelsenIndustry
NCT07871877 · 60 participants (planned) · Start Jul 1, 2027 · Primary completion Jan 31, 2029
Drug: Ibogaine Hydrochloride; Extended-release naltrexone injection, 380 mg and 2 more · For: Opioid Use Disorder; Opioid Withdrawal; Substance Use Disorders
Sites: Basalt, Colorado
- Evaluation of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent PersonsNot yet recruiting
Go Medical Industries Pty LtdIndustry
NCT05382091 · 250 participants (planned) · Start Jan 1, 2027 · Primary completion Jul 1, 2029
Drug: naltrexone implant · For: Opioid Use Disorder
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Brexpiprazole for Extended-Release Injection in Subjects With SchizophreniaPivotal-lookingNot yet recruiting
Bostal Drug Delivery Co., LtdIndustry
NCT07742280 · 16 participants (planned) · Start Aug 2026 · Primary completion Aug 2027
Drug: Brexpiprazole for ER injection, 45 mg; Brexpiprazole for ER injection, 100 mg · For: Schizophrenia
- A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With SchizophreniaPivotal-lookingNot yet recruiting
Bostal Drug Delivery Co., LtdIndustry
NCT07722728 · 84 participants (planned) · Start Aug 2026 · Primary completion Aug 2027
Drug: 30 mg B2227; 70 mg B2227 and 5 more · For: Schizophrenia
- Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia AdultsPivotal-lookingNot yet recruiting
Vigonvita Life SciencesIndustry
NCT07703956 · 500 participants (planned) · Start Jul 31, 2026 · Primary completion Oct 31, 2027
Drug: VV119 2mg; VV119 4mg and 3 more · For: Schizophrenia
Sites: Beijing, China
- Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar DepressionPivotal-lookingNot yet recruiting
Neurocentrx Pharma Pty LtdIndustry
NCT07644767 · 160 participants (planned) · Start Oct 30, 2026 · Primary completion Jan 30, 2028
Drug: KET-AD · For: Treatment Resistant Bipolar Depression
- A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398Not yet recruiting
Shanghai Zhongze Therapeutics Co., Ltd.Industry
NCT07626034 · 9 participants (planned) · Start Aug 2026 · Primary completion Oct 2027
Drug: SIPI6398 Tablets · For: Schizophrenia Disorder
BioLite, Inc.Industry
NCT03833206 · 12 participants (planned) · Start Jan 15, 2027 · Primary completion Feb 28, 2028
Drug: PDC-1421 Capsule · For: Major Depressive Disorder
Sites: Los Angeles, California
- A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe DepressionPivotal-lookingNot yet recruiting
Tasly Pharmaceutical Group Co., LtdIndustry
NCT07485595 · 180 participants (planned) · Start Apr 30, 2026 · Primary completion Dec 31, 2026
Drug: Placebo group; JS1-1-01 low-dose group and 1 more · For: Depression
Sites: Beijing, China
- ENA-001 for Post Operative Respiratory Depression (PORD)Pivotal-lookingNot yet recruiting
Enalare Therapeutics Inc.Industry
NCT06137638 · 200 participants (planned) · Start Dec 15, 2026 · Primary completion Jun 15, 2027
Drug: ENA-001 · For: Respiratory Depression
- A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With SchizophreniaPivotal-lookingNot yet recruiting
Luye Pharma Group Ltd.Industry
NCT07396870 · 160 participants (planned) · Start Mar 31, 2026 · Primary completion Dec 31, 2027
Drug: LY03020; Placebo · For: Schizophrenia
Sites: Beijing, China
- A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use DisorderNot yet recruiting
Afasci IncIndustry
NCT06710431 · 36 participants (planned) · Start Oct 1, 2025 · Primary completion Jun 1, 2027
Drug: AFA-281 · For: Alcohol Abuse; Alcohol Abuse/addiction; Anxiety and 3 more
Sites: Los Angeles, California
Filament Health Corp.Industry
NCT06608459 · 10 participants (planned) · Start Dec 2024 · Primary completion Dec 2026
Drug: PEX010-Assisted Therapy · For: Opioid Use Disorder
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.